Gilead Says Trodelvy Reduces Risk Of Disease Progression Or Death By 38% Versus. Chemotherapy In Ascent-03 Study For Breast Cancer Treatment

Reuters
2025.10.19 06:33
portai
I'm PortAI, I can summarize articles.

Oct 19 (Reuters) - Gilead Sciences Inc:GILEAD: TRODELVY REDUCES RISK OF DISEASE PROGRESSION OR DEATH BY 38% VERSUS. CHEMOTHERAPY IN ASCENT-03 STUDY FOR BREAST CANCER TREATMENTGILEAD: IN ASCENT-03 STUDY, MEDIAN PROGRESSION-FREE SURVIVAL (PFS) WITH TRODELVY WAS 9.7 MONTHS VERSUS. 6.9 MONTHS FOR CHEMOTHERAPYGILEAD: IN ASCENT-03 STUDY, OVERALL SURVIVAL (OS) DATA WERE NOT MATURE AT THE TIME OF PFS PRIMARY ANALYSIS; WILL CONTINUE TOMONITOR OS OUTCOMES Source: here Further company coverage:

Oct 19 (Reuters) - Gilead Sciences Inc (GILD.O) :

  • GILEAD: TRODELVY REDUCES RISK OF DISEASE PROGRESSION OR DEATH BY 38% VERSUS. CHEMOTHERAPY IN ASCENT-03 STUDY FOR BREAST CANCER TREATMENT
  • GILEAD: IN ASCENT-03 STUDY, MEDIAN PROGRESSION-FREE SURVIVAL (PFS) WITH TRODELVY WAS 9.7 MONTHS VERSUS. 6.9 MONTHS FOR CHEMOTHERAPY
  • GILEAD: IN ASCENT-03 STUDY, OVERALL SURVIVAL (OS) DATA WERE NOT MATURE AT THE TIME OF PFS PRIMARY ANALYSIS; WILL CONTINUE TOMONITOR OS OUTCOMES Source: here Further company coverage: (GILD.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.